Q3 Sales Rise 6.5% on Hot Summer, But Unchanged Guidance Leaves Shares 1% Lower
CCEP sits 34% above its 52-week low of $84.655.
Summary
CCEP posted Q3 revenue of €5.7bn, up 6.5%, with volumes up an above-forecast 3.6% to 1.05bn unit cases and revenue per case up 2.2% to €5.46. Growth was broad: France/Benelux, its biggest market, rose 5.7% to €1.5bn and Great Britain jumped 9.3% to £1bn. CEO Damian Gammell credited zero sugar, energy and hydration demand plus favorable European weather, while calling the consumer environment challenging and flagging geopolitical pressure on operating costs. Full-year guidance was left unchanged — 3-4% revenue growth, cost of sales per case up about 1.5%, operating profit growth around 7% — and the stock slipped 1% in London and pre-market in New York. Jefferies, at Buy, attributed the weakness to the strong run and the absence of an upgrade rather than the numbers themselves. The company also declared a second-half interim dividend of €1.42 per share, payable 3 December 2026 to holders of record 20 November, for a full-year dividend of €2.24.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — CCEP declared a second-half interim dividend of €1.42 per share, payable 3 December 2026 to holders of record 20 November, for a full-year dividend of €2.24.
At the time of this announcement, CCEP was trading at $113.69 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $51.2B. The 52-week trading range was $84.66 to $116.01. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ShareCast.